Fluoxetine potentiation of methylphenidate-induced neuropeptide expression in the striatum occurs selectively in direct pathway (striatonigral) neurons.

Fluoxetine potentiation of methylphenidate-induced neuropeptide expression in the striatum occurs selectively in direct pathway (striatonigral) neurons.
复制标题

氟西汀对纹状体中哌醋甲酯诱导的神经肽表达的增强选择性地发生在直接通路(纹状体黑质)神经元中。

DOI:
10.1111/j.1471-4159.2012.07852.x
复制
发表时间:
2012-09
影响因子:
4.7
通讯作者:
Steiner H
Steiner H
中科院分区:
医学2区
文献类型:
--
作者:
Van Waes V;Carr B;Beverley JA;Steiner H

文献摘要

参考文献

被引文献

相似文献

Concomitant therapies combining psychostimulants such as methylphenidate and selective serotonin reuptake inhibitors (SSRIs) are used to treat several mental disorders, including attention-deficit hyperactivity disorder/depression comorbidity. The neurobiological consequences of these drug combinations are poorly understood. Methylphenidate alone induces gene regulation that mimics partly effects of cocaine, consistent with some addiction liability. We previously showed that the SSRI fluoxetine potentiates methylphenidate-induced gene regulation in the striatum. The present study investigated which striatal output pathways are affected by the methylphenidate + fluoxetine combination, by assessing effects on pathway-specific neuropeptide markers. Results demonstrate that fluoxetine (5 mg/kg) potentiates methylphenidate (5 mg/kg)-induced expression of substance P and dynorphin, markers for direct pathway neurons. In contrast, no drug effects on the indirect pathway marker enkephalin were found. Because methylphenidate alone has minimal effects on dynorphin, the potentiation of dynorphin induction represents a more cocaine-like effect for the drug combination. On the other hand, the lack of an effect on enkephalin suggests a greater selectivity for the direct pathway compared with psychostimulants such as cocaine. Overall, the fluoxetine potentiation of gene regulation by methylphenidate occurs preferentially in sensorimotor striatal circuits, similar to other addictive psychostimulants. These results suggest that SSRIs may enhance the addiction liability of methylphenidate.
DOI: 10.1016/0376-8716(94)01065-s
发表时间: 1995-02-01
影响因子: 4.2
作者:
HANSON, GR;SINGH, N;GIBB, JW
通讯作者: GIBB, JW
DOI: 10.1016/j.neuropharm.2008.04.019
发表时间: 2008-07-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Frankel, Paul S.;Alburges, Mario E.;Kish, Stephen J.
通讯作者: Kish, Stephen J.
DOI: 10.1016/s0893-133x(01)00281-0
发表时间: 2001-11-01
影响因子: 7.6
作者:
Brandon, CL;Marinelli, M;White, FJ
通讯作者: White, FJ
DOI: 10.1126/science.2147780
发表时间: 1990-12-07
期刊: SCIENCE
影响因子: 56.9
作者:
GERFEN, CR;ENGBER, TM;SIBLEY, DR
通讯作者: SIBLEY, DR
DOI: 10.1046/j.1460-9568.2003.02892.x
发表时间: 2003-09-01
影响因子: 3.4
作者:
Brandon, CL;Steiner, H
通讯作者: Steiner, H